Table 1 |
|||||
|
Subject characteristics and outcomes between groups |
|||||
|
Variables |
Total (n = 146) |
Control (n = 49) |
CHX*1 (n = 47) |
CHX*2 (n = 50) |
P value |
|
|
|||||
|
Age (years) |
48.0 ± 20.8 |
50.0 ± 22.5 |
44.8 ± 19.9 |
47.6 ± 19.1 |
0.3948 |
|
Gender – male/female |
104/42 |
36/23 |
43/15 |
44/14 |
0.1570 |
|
Race |
0.3661 |
||||
|
White |
117 (88%) |
43 (88%) |
37 (78%) |
37 (74%) |
|
|
African American |
24 (17%) |
4 (8%) |
10 (22%) |
10 (20%) |
|
|
Asian |
2 (1%) |
1 (2%) |
0 (0%) |
1 (2%) |
|
|
American Indian |
3 (1%) |
1 (2%) |
0 (0%) |
2 (4%) |
|
|
Admitted from |
0.0989 |
||||
|
Internal hospital ward |
6 (4%) |
5 (10%) |
1 (25) |
0 (0%) |
|
|
External community |
116 (80%) |
38 (76%) |
37 (79%) |
41 (82%) |
|
|
Other |
24 (16%) |
6 (12%) |
9 (19%) |
9 (18%) |
|
|
Co-morbidities |
68 (47%)* |
24 (50%) |
19 (40%) |
25 (51%) |
0.5212 |
|
Cardiac |
35 (24%) |
13 (27%) |
10 (21%) |
12 (25%) |
0.8039 |
|
Pulmonary |
16 (11%) |
7 (15%) |
3 (6%) |
6 (12%) |
0.4245 |
|
Renal |
5 (3%) |
2 (4%) |
0 (0%) |
3 (6%) |
0.2483 |
|
Hepatic |
2 (1%) |
2 (4%) |
0 (0%) |
0 (0%) |
0.1316 |
|
Endocrine |
24 (17%) |
10 (21%) |
6 (13%) |
8 (16%) |
0.5715 |
|
Central nervous |
21 (15%) |
9 (19%) |
8 (17%) |
4 (8%) |
0.2844 |
|
Neoplastic |
10 (7%) |
4 (8%) |
2 (4%) |
4 (8%) |
0.6764 |
|
Immunosuppression |
2 (1%) |
0 (0%) |
0 (0%) |
2 (4%) |
0.1400 |
|
APACHE (baseline) |
19.1 ± 5.5 |
19.1 ± 6.1 |
18.5 ± 4.1 |
19.7 ± 6.1 |
0.5850 |
|
Antibiotic exposure before study inclusion |
43 (29%) |
18 (37%) |
12 (26%) |
13 (26%) |
0.3896 |
|
Antibiotic exposure after study inclusion |
103 (71%) |
32 (65%) |
34 (72%) |
37 (74%) |
0.6043 |
|
Antibiotic use |
3.5 ± 3.6 |
3.1 ± 3.5 |
3.8 ± 3.6 |
3.7 ± 3.8 |
0.6057 |
|
Days ventilated |
9.1 ± 5.6 |
9.7 ± 6.3 |
9.4 ± 5.0 |
8.4 ± 5.2 |
0.5180 |
|
Days in hospital |
11.4 ± 6.6 |
11.3 ± 6.7 |
12.0 ± 6.3 |
11.0 ± 6.8 |
0.7263 |
|
Deaths |
24 (17%) |
8 (17%) |
8 (17%) |
8 (16%) |
0.9834 |
|
Missing doses |
0.7 ± 1.1 |
0.9 ± 1.2 |
0.7 ± 1.3 |
0.5 ± 0.8 |
0.2844 |
|
|
|||||
|
*Some patients had multi-comorbidities. APACHE = Acute Physiology and Chronic Health Evaluation; CHX = chlorhexidine gluconate. |
|||||
|
Scannapieco et al. Critical Care 2009 13:R117 doi:10.1186/cc7967 |
|||||
